Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller.

Additionally, a listen-only webcast will be available by clicking here.

A replay of the call will be available on the Investors / Events tab of Corcept.com.

About Corcept Therapeutics

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders. We have discovered more than 1,000 proprietary selective glucocorticoid receptor antagonists. Our development activities include advanced clinical trials in patients with hypercortisolism, a variety of solid tumors, ALS and liver disease. In 2012, we introduced Korlym^®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous Cushing’s syndrome. In March 2026, we introduced Lifyorli^® as a treatment for patients with platinum-resistant ovarian cancer. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist. We are headquartered in Redwood City, California. For more information, visit Corcept.com.

Investor inquiries:
ir@corcept.com

Media inquiries:
communications@corcept.com
www.corcept.com